Peptide Schedule
CortexinSmall moleculeNo amino acid sequence. Icon reflects category theme only.Cortexin
Benefits
About Cortexin
Cortexin is a polypeptide bioregulator complex derived from the cerebral cortex of young cattle or pigs through acid extraction and purification. Developed at the Institute of Bioregulation and Gerontology in St. Petersburg, it belongs to the class of Khavinson peptide bioregulators — short-chain peptides believed to interact with specific gene promoter regions to modulate protein expression in target tissues. The preparation contains a standardized mixture of neuropeptides with molecular weights below 10 kDa, along with L-glycine, vitamins, and trace minerals. Cortexin was first registered in Russia in 1999 and has since become one of the most prescribed neuroprotective agents in the Russian Federation and neighboring countries. Clinical use spans a wide range of neurological conditions. In acute ischemic stroke, randomized controlled trials have demonstrated that adding Cortexin to standard therapy improves neurological deficit scores, accelerates functional recovery, and reduces 30-day mortality compared to placebo. For traumatic brain injury, studies show benefits in cognitive restoration, reduction of post-traumatic epilepsy risk, and improved Glasgow Outcome Scale scores at follow-up. In pediatric neurology, Cortexin has been studied for perinatal brain injury, delayed speech and psychomotor development, epilepsy, and attention deficit disorders, with multiple Russian clinical trials reporting positive outcomes. The proposed mechanism centers on tissue-specific gene regulation: the peptide fragments are thought to penetrate neuronal membranes and interact with chromatin, restoring optimal expression of neurotrophic factors such as BDNF and NGF while normalizing the balance between excitatory and inhibitory neurotransmission. Cortexin also exhibits antioxidant activity, reduces glutamate excitotoxicity, and stabilizes neuronal membrane potential under ischemic conditions. While the evidence base is large within Russian-language medical literature — with over 200 published studies — international peer-reviewed data remains limited, and no FDA-equivalent regulatory approval exists outside the CIS region.
Who Should Consider Cortexin
- Post-ischemic stroke patients in recovery phase
- Traumatic brain injury patients
- Adults with age-related cognitive decline
- Children with perinatal brain injury or neurodevelopmental delays
- Patients with chronic cerebrovascular insufficiency
- Individuals recovering from neurosurgical procedures
How Cortexin Works
Cortexin operates through multiple interconnected pathways owing to its nature as a polypeptide complex rather than a single molecular entity. The primary proposed mechanism involves tissue-specific bioregulation at the genomic level: short-chain peptides in the 1-10 kDa range are believed to cross cell membranes and interact with promoter regions of genes encoding neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). This interaction upregulates neurotrophin expression, promoting neuronal survival, synaptic plasticity, and axonal regeneration. At the receptor level, Cortexin modulates the balance between glutamatergic excitation and GABAergic inhibition. Under ischemic conditions, it reduces pathological glutamate release and attenuates NMDA receptor-mediated calcium influx, thereby limiting excitotoxic neuronal death. Electrophysiological studies show normalization of cortical bioelectrical activity and improved interhemispheric coherence on EEG following treatment. Cortexin also demonstrates direct antioxidant properties, scavenging reactive oxygen species and enhancing endogenous antioxidant enzyme activity including superoxide dismutase and glutathione peroxidase. This reduces lipid peroxidation in neuronal membranes, preserving membrane integrity during oxidative stress. Additional mechanisms include stabilization of mitochondrial membrane potential, reduction of apoptotic signaling via caspase-3 downregulation, and modulation of inflammatory cytokines including IL-1beta and TNF-alpha in injured brain tissue.
What to Expect
Minimal noticeable effects. Some patients report mild psychomotor activation or slight headache as the polypeptide complex begins to act.
Gradual improvements in mental clarity, attention, and alertness. Stroke patients may begin showing measurable improvements on neurological deficit scales.
Peak benefits of the treatment course. Improved cognitive function, better EEG patterns, and continued neurological recovery in stroke and TBI patients.
Effects persist and may continue to improve after the injection course ends due to ongoing gene expression changes and neurotrophic factor upregulation.
Cumulative benefits with repeated treatment courses. Clinical studies show progressive improvement with each successive 10-day course over a 12-month period.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 10mg | 2x Daily |
Note: Cortexin is a lyophilized polypeptide fraction extracted from the cerebral cortex of cattle or pigs. It has been approved in Russia since 1999 and is widely used across CIS countries for neurological conditions including ischemic stroke, traumatic brain injury, and cognitive impairment. Standard treatment courses are 10 days of daily intramuscular injections, repeated 2-4 times per year. Because Cortexin is a complex mixture of low-molecular-weight neuropeptides, amino acids, vitamins, and minerals rather than a single defined peptide, pharmacokinetic characterization of individual components is limited.
How to Inject Cortexin
Reconstitute one vial of lyophilized Cortexin with 1-2 mL of sterile water for injection or 0.5% procaine (novocaine) solution to reduce injection pain. Gently swirl until fully dissolved — do not shake vigorously. Administer via deep intramuscular injection into the deltoid or gluteal muscle. Inject slowly over 1-2 minutes. Rotate injection sites daily. Standard adult dose is 10 mg once daily for 10 consecutive days. Pediatric dose (children under 20 kg) is 0.5 mg/kg/day, not exceeding 10 mg. Treatment courses are repeated every 3-6 months as indicated. Morning administration is preferred to minimize potential sleep disturbances. Reconstituted solution should be used immediately and not stored.
Cycling Protocol
Standard Russian protocol: 10-day treatment course (daily IM injections), repeated 2-4 times per year with at least 3-month intervals between courses. Acute conditions may use two courses back-to-back with a 10-day break.
Pharmacokinetics
Source: Estimated from polypeptide fraction kinetics; individual component PK not fully characterized (Skoromets et al., 2018)
Loading the interactive decay curve.
Side Effects
Cortexin is generally well tolerated in clinical studies, with adverse events reported at rates comparable to placebo. The most commonly noted side effects include mild injection site pain or irritation, transient headache, and occasional dizziness shortly after administration. Allergic reactions including local urticaria and skin rash have been reported rarely, primarily in individuals with known sensitivity to animal-derived proteins. Because the preparation is derived from bovine or porcine brain tissue, theoretical prion-related concerns exist, though no cases have been documented in decades of clinical use. Some patients report transient psychomotor agitation or sleep disturbances during the first few days of a treatment course, which typically resolve without intervention.
Contraindications
- Pregnancy and breastfeeding (insufficient safety data)
- Known hypersensitivity to Cortexin or animal-derived brain peptides
- Severe allergic history to bovine or porcine proteins
- Active anaphylactic conditions
- Individual intolerance to glycine or other excipients
Drug Interactions
- No significant drug interactions have been reported in clinical literature
- Compatible with standard stroke therapy including anticoagulants and antihypertensives
- May be combined with Cerebrolysin though no formal interaction studies exist
- Use caution with other CNS-active peptides — additive neurostimulatory effects possible
- Procaine diluent should not be used in patients with known local anesthetic allergy
Storage & Stability
Related Peptides
References
- Cortexin in the treatment of acute ischemic stroke: results of a multicenter randomized double-blind placebo-controlled studyPubMed 29652367
- Neuroprotective effects of cortexin in acute period of ischemic strokePubMed 25907853
- Cortexin — a multi-modal neuroprotective peptide bioregulator: evidence from clinical and experimental studiesPubMed 30273182
- Efficacy and safety of cortexin in the treatment of cognitive disorders in patients with chronic cerebral ischemiaPubMed 27735955
- Cortexin in pediatric neurology: clinical applications in perinatal brain injuryPubMed 23319139
- Bioregulatory peptides of the Khavinson group: mechanisms of action and clinical perspectivesPubMed 31544366